Global Scientific Evolution and Knowledge Mapping of Emerging Extended-Spectrum Beta-Lactamase Inhibitors: A Scientometric Analysis

Abstract

Bacterial resistance to available antibiotics has increasingly become a critical issue, necessitating the search for novel inhibitors to combat resistant pathogens, particularly gram-negative bacteria. This bibliometric study aims to analyze the scientific literature on novel inhibitors for extended spectrum beta-lactamase (ESBL) enzymes, identifying the most prolific organizations, authors, journals, countries, and keywords within this research area. Data were retrieved from Dimensions and Scopus databases, with 503 out of 2086 papers (published between 2013 and 2023) meeting the inclusion criteria. Analysis and visualization were performed using R-studio software and VOSviewer©, focusing on article titles, publication years, countries, authors, journals, and keywords. The study found that the United States led in the number of publications (445) and citations (15,889), followed by France and China. The journal Antimicrobial Agents and Chemotherapy published the most articles (171) and received the highest citations. Indiana University Bloomington and Case Western Reserve University from the U.S. were the leading institutions. Robert Bonomo authored the most papers , while Karen Bush was the highest-cited author (1,955 citations). Key future research hotspots include "taniborbactam," "xeruborbactam," "enmetazobactam," "VNRX-5236," and "imipenem-relebactam." This study underscores the critical global efforts and contributions in developing novel inhibitors against ESBL enzymes. The findings highlight key authors, influential journals, and emerging research directions that can guide future studies in combating antibiotic resistance among gram-negative bacteria.